Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michelle Milella"'
Autor:
Stephen L. Abrams, Melchiorre Cervello, Piotr Laidler, Ferdinando Nicoletti, Matilde Y. Follo, Agnieszka Gizak, Giuseppe Montalto, James A. McCubrey, Lucio Cocco, Kvin Lertpiriyapong, Joanna Dulińska-Litewka, Massimo Libra, Linda S. Steelman, Zoya N. Demidenko, Danijela Maksimović-Ivanić, Alberto M. Martelli, Agustino Tafuri, Saverio Candido, Luca M. Neri, Sandra Marmiroli, Dariusz Rakus, Michelle Milella, Joerg Basecke, Aurora Scalisi, Concettina Fenga, Sanja Mijatović, Timothy L. Fitzgerald, Lyudmyla Drobot
Publikováno v:
Scopus-Elsevier
Current Pharmaceutical Design
Current Pharmaceutical Design
The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ee19fe79bdabcbbeb752ef81f105d76
http://hdl.handle.net/11573/909740
http://hdl.handle.net/11573/909740
Autor:
Kathleen I. Pritchard, Sonal Gandhi, Sunil Verma, Francesco Cognetti, Paolo Carlini, Diana Giannarelli, Emilio Bria, Michelle Milella, Cecilia Nisticò, Edmondo Terzoli, Federica Cuppone
Publikováno v:
Cancer. 112:260-267
BACKGROUND. Despite the advantages from using aromatase inhibitors (AIs) compared with tamoxifen for early breast cancer, an unexpectedly greater number of grade 3 and 4 cardiovascular events (CVAE) (as defined by National Cancer Institute of Canada-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67139e147acd00e64d74d9000edd0b6
https://doi.org/10.1002/cncr.23171
https://doi.org/10.1002/cncr.23171
Autor:
Santiago Artillo, Giuseppe Pastore, Michelle Milella, Giovanna Fattovich, Vicente Carreño, Giuliano Giustina, Jean-Charles Ryff, Teresa Santantonio, Monique Chaneac, Javier Bartolomé, Alfredo Alberti
Publikováno v:
Journal of Medical Virology. 54:167-172
Pilot studies have demonstrated that recombinant interleukin 2 (rIL-2) has an indirect antiviral activity against hepatitis B virus, but the minimal dose of rIL-2 for induction of this effect was not defined. The aim of the study was to ascertain the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e54612bdce052eab4a8202af63f86f
https://doi.org/10.1002/(sici)1096-9071(199803)54:3<167::aid-jmv4>3.0.co
https://doi.org/10.1002/(sici)1096-9071(199803)54:3<167::aid-jmv4>3.0.co